NTHL1 and colorectal carcinoma: On the other hand, patients carrying AXIN2 or NTHL1 mutations have an elevated CRC risk compared to the general population, although the level of risk remains uncertain due to the low prevalence reported thus far, complicating patient management and genetic counseling.